Browse FAM101A

Summary
SymbolFAM101A
Namefamily with sequence similarity 101, member A
Aliases FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton Note=Colocalizes with FLNA along actin bundle-like structures.
Domain PF15068 FAM101 family
Function

Involved in the regulation of the perinuclear actin network and nuclear shape through interaction with filamins. Plays an essential role in actin cytoskeleton formation in developing cartilaginous cells.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001503 ossification
GO:0002062 chondrocyte differentiation
GO:0002063 chondrocyte development
GO:0007015 actin filament organization
GO:0010721 negative regulation of cell development
GO:0021700 developmental maturation
GO:0030278 regulation of ossification
GO:0030279 negative regulation of ossification
GO:0030282 bone mineralization
GO:0030500 regulation of bone mineralization
GO:0030502 negative regulation of bone mineralization
GO:0031214 biomineral tissue development
GO:0032330 regulation of chondrocyte differentiation
GO:0032331 negative regulation of chondrocyte differentiation
GO:0035630 bone mineralization involved in bone maturation
GO:0043931 ossification involved in bone maturation
GO:0048705 skeletal system morphogenesis
GO:0048799 animal organ maturation
GO:0051216 cartilage development
GO:0060348 bone development
GO:0061035 regulation of cartilage development
GO:0061037 negative regulation of cartilage development
GO:0061181 regulation of chondrocyte development
GO:0061182 negative regulation of chondrocyte development
GO:0061448 connective tissue development
GO:0061572 actin filament bundle organization
GO:0070167 regulation of biomineral tissue development
GO:0070168 negative regulation of biomineral tissue development
GO:0070977 bone maturation
GO:0071695 anatomical structure maturation
GO:1900157 regulation of bone mineralization involved in bone maturation
GO:1900158 negative regulation of bone mineralization involved in bone maturation
GO:1903010 regulation of bone development
GO:1903011 negative regulation of bone development
Molecular Function GO:0031005 filamin binding
Cellular Component GO:0015629 actin cytoskeleton
GO:0032432 actin filament bundle
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolFAM101A
Namefamily with sequence similarity 101, member A
Aliases FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FAM101A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolFAM101A
Namefamily with sequence similarity 101, member A
Aliases FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FAM101A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFAM101A
Namefamily with sequence similarity 101, member A
Aliases FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FAM101A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7750.0513
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.4720.0267
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2520.65
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5180.324
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8140.444
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1520.913
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 482.1980.0335
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.9760.0272
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 6823001
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FAM101A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFAM101A
Namefamily with sequence similarity 101, member A
Aliases FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FAM101A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFAM101A
Namefamily with sequence similarity 101, member A
Aliases FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FAM101A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FAM101A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFAM101A
Namefamily with sequence similarity 101, member A
Aliases FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FAM101A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFAM101A
Namefamily with sequence similarity 101, member A
Aliases FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FAM101A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFAM101A
Namefamily with sequence similarity 101, member A
Aliases FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FAM101A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFAM101A
Namefamily with sequence similarity 101, member A
Aliases FLJ44614; protein FAM101A; refilinA; regulator of filamin protein A; Filamin-interacting protein FAM101A
Chromosomal Location12q24.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FAM101A collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.